Company: NDRA
Filing Date: 2025-10-30
Form Type: 424B5
Source: 0001213900-25-103705
Chunk: 44

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 424B5
Chunk 44
---
 approval;   |

| ● | our ability to obtain CE mark certification and secure required FDA and other governmental approvals for our Thermo-Acoustic Enhanced 
 Ultrasound (“TAEUS”) applications                                                                                                     |

| ● | our ability to develop a commercially feasible application based on our TAEUS technology; |

| ● | market acceptance of our technology; |

| ● | uncertainties associated with COVID-19 or other pandemics that may occur, including effects on our operations; |

| ● | the effect of macroeconomic conditions on our business; |

| ● | results of our human studies, which may be negative or inconclusive; |

| ● | our ability to find and maintain development partners; |

| ● | our reliance on third parties, collaborations, strategic alliances and licensing arrangements to complete our business strategy; |

<div align='center'>2</div>

| ● | the amount and nature of competition in our industry; |

| ● | our ability to protect our intellectual property; |

| ● | potential changes in the healthcare industry or third-party reimbursement practices; |

| ● | our ability to comply with regulation by various federal, state, local and foreign governmental agencies and to maintain necessary 
 regulatory clearances or approvals;                                                                                                |

| ● | our ability to maintain compliance with Nasdaq listing standards; |

| ● | our dependence on our senior management team; and |

| ● | the other risks and uncertainties described in the Risk Factors section of this prospectus, any prospectus supplement and our most 
 recent Annual Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, which filings are incorporated herein by reference. |

We urge you to consider those risks and uncertainties
in evaluating our forward-looking statements. All subsequent written and oral forward-looking statements attributable to us or to persons
acting on our behalf are expressly qualified in their entirety by the applicable cautionary statements. We further caution readers not
to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by
the federal securities laws, we undertake no obligation to publicly update any forward-looking statement, whether written or oral, that
may be made from time to time, whether as a result of new information, future developments or otherwise.

<div align='center'>3

THE COMPANY</div>

We were incorporated as a Delaware corporation
in 2007. We are developing a next-generation enhanced ultrasound technology platform—Thermo Acoustic Enhanced Ultrasound, or TAEUS
in order to broaden patient access to